ES2172533T3 - Uso de nonapeptidos y decapeptidos para la preparacion de un medicamento para combatir el sida. - Google Patents

Uso de nonapeptidos y decapeptidos para la preparacion de un medicamento para combatir el sida.

Info

Publication number
ES2172533T3
ES2172533T3 ES94913518T ES94913518T ES2172533T3 ES 2172533 T3 ES2172533 T3 ES 2172533T3 ES 94913518 T ES94913518 T ES 94913518T ES 94913518 T ES94913518 T ES 94913518T ES 2172533 T3 ES2172533 T3 ES 2172533T3
Authority
ES
Spain
Prior art keywords
preparation
decapeptides
nonapeptides
pct
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94913518T
Other languages
English (en)
Inventor
Jurgen Engel
Bernhard Kutscher
Michael Bernd
Ulf Niemeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Application granted granted Critical
Publication of ES2172533T3 publication Critical patent/ES2172533T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A61K38/105—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LOS NONA Y DECAPEPTIDOS ANTAGONISTICOS LHRH Y ANTAGONISTICOS BOMBESINA SON APROPIADOS PARA LA ELABORACION DE UN MEDICAMENTO PARA LA LUCHA CONTRA EL SIDA Y ARC, ASI COMO PARA LA ELABORACION DE UN MEDICAMENTO DE INMUNOESTIMULACION.
ES94913518T 1993-06-18 1994-04-02 Uso de nonapeptidos y decapeptidos para la preparacion de un medicamento para combatir el sida. Expired - Lifetime ES2172533T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4320201A DE4320201A1 (de) 1993-06-18 1993-06-18 Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation

Publications (1)

Publication Number Publication Date
ES2172533T3 true ES2172533T3 (es) 2002-10-01

Family

ID=6490614

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94913518T Expired - Lifetime ES2172533T3 (es) 1993-06-18 1994-04-02 Uso de nonapeptidos y decapeptidos para la preparacion de un medicamento para combatir el sida.

Country Status (24)

Country Link
US (1) US5985834A (es)
EP (1) EP0703786B1 (es)
JP (1) JPH08511784A (es)
KR (1) KR100352541B1 (es)
CN (1) CN1136915C (es)
AT (1) ATE213164T1 (es)
AU (1) AU688315B2 (es)
BR (1) BR9406893A (es)
CZ (1) CZ285997B6 (es)
DE (2) DE4320201A1 (es)
DK (1) DK0703786T3 (es)
ES (1) ES2172533T3 (es)
FI (1) FI113008B (es)
HU (1) HUT73673A (es)
IL (1) IL110045A (es)
NO (1) NO320945B1 (es)
PL (1) PL175580B1 (es)
PT (1) PT703786E (es)
RU (1) RU2154492C2 (es)
SG (1) SG52240A1 (es)
TW (1) TW370532B (es)
UA (1) UA41938C2 (es)
WO (1) WO1995000168A1 (es)
ZA (1) ZA944347B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
DE19728737C1 (de) * 1997-07-04 1999-02-11 Johannes Christian Groeninghen Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten
US8962558B2 (en) 1997-07-04 2015-02-24 Johannes C. van Groeninghen Methods for reducing GnRH-positive tumor cell proliferation using the GnRH antagonist IN3
RU2248982C9 (ru) * 2000-03-14 2005-06-10 Центарис Гмбх Антагонисты lhrh, их получение, фармацевтическая композиция и ее получение, способ лечения опухолей и бесплодия у млекопитающих
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
US20040138138A1 (en) * 2001-08-02 2004-07-15 Jurgen Engel Use of LHRH-antagonists in doses that do not cause castration for the improvement of T-cell mediated immunity
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20110129532A1 (en) * 2008-05-29 2011-06-02 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
CA2730068A1 (en) 2008-07-07 2010-01-14 Oxford Nanopore Technologies Limited Base-detecting pore
CN102245760A (zh) 2008-07-07 2011-11-16 牛津纳米孔技术有限公司 酶-孔构建体
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
CN102482330A (zh) * 2009-01-30 2012-05-30 牛津纳米孔技术有限公司 酶突变体
CA2750879C (en) 2009-01-30 2018-05-22 Oxford Nanopore Technologies Limited Adaptors for nucleic acid constructs in transmembrane sequencing
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
KR101939420B1 (ko) 2011-02-11 2019-01-16 옥스포드 나노포어 테크놀로지즈 리미티드 돌연변이체 세공
KR20140050067A (ko) 2011-07-25 2014-04-28 옥스포드 나노포어 테크놀로지즈 리미티드 막횡단 포어를 사용한 이중 가닥 폴리뉴클레오티드 서열분석을 위한 헤어핀 루프 방법
JP6271505B2 (ja) 2012-04-10 2018-01-31 オックスフォード ナノポール テクノロジーズ リミテッド 変異体ライセニンポア
WO2014013259A1 (en) 2012-07-19 2014-01-23 Oxford Nanopore Technologies Limited Ssb method
CN105209634B (zh) 2013-03-08 2020-05-12 牛津纳米孔技术公司 酶停滞方法
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
CN106459159B (zh) 2014-05-02 2021-11-30 牛津纳米孔技术公司 突变孔
CN114605507A (zh) 2014-09-01 2022-06-10 弗拉芒区生物技术研究所 突变csgg孔
US10266885B2 (en) 2014-10-07 2019-04-23 Oxford Nanopore Technologies Ltd. Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
CN105837674A (zh) * 2016-03-08 2016-08-10 无限极（中国）有限公司 一种东方铃蟾多肽及其制备方法与应用
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677193A (en) * 1985-02-22 1987-06-30 The Salk Institute For Biological Studies Peptides containing an aliphatic-aromatic ketone side chain
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
AU618029B2 (en) * 1987-11-02 1991-12-12 Imperial Chemical Industries Plc Polypeptide compounds
WO1989009229A1 (en) * 1988-03-31 1989-10-05 Immunobiology Research Institute, Inc. Treatment of hiv viremic patients with thymopentin
HU208439B (en) * 1988-10-14 1993-10-28 Univ Tulane Process for producing pharmaceutical peptides
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Also Published As

Publication number Publication date
US5985834A (en) 1999-11-16
ZA944347B (en) 1995-02-15
FI956014A0 (fi) 1995-12-14
PL175580B1 (pl) 1999-01-29
WO1995000168A1 (de) 1995-01-05
PL312219A1 (en) 1996-04-01
IL110045A (en) 2000-06-01
ATE213164T1 (de) 2002-02-15
NO954996D0 (no) 1995-12-08
FI113008B (fi) 2004-02-27
RU2154492C2 (ru) 2000-08-20
JPH08511784A (ja) 1996-12-10
CZ285997B6 (cs) 1999-12-15
DK0703786T3 (da) 2002-05-27
BR9406893A (pt) 1996-09-10
EP0703786B1 (de) 2002-02-13
DE4320201A1 (de) 1995-01-12
EP0703786A1 (de) 1996-04-03
SG52240A1 (en) 1998-09-28
NO954996L (no) 1995-12-08
HU9503605D0 (en) 1996-02-28
KR100352541B1 (ko) 2002-12-26
AU6564794A (en) 1995-01-17
UA41938C2 (uk) 2001-10-15
CN1125400A (zh) 1996-06-26
CN1136915C (zh) 2004-02-04
IL110045A0 (en) 1994-10-07
HUT73673A (en) 1996-09-30
TW370532B (en) 1999-09-21
DE59410052D1 (de) 2002-03-21
PT703786E (pt) 2002-07-31
NO320945B1 (no) 2006-02-20
CZ308995A3 (en) 1996-03-13
FI956014A (fi) 1995-12-14
AU688315B2 (en) 1998-03-12
KR960703015A (ko) 1996-06-19

Similar Documents

Publication Publication Date Title
ES2172533T3 (es) Uso de nonapeptidos y decapeptidos para la preparacion de un medicamento para combatir el sida.
HK1028594A1 (en) Adamantane derivatives
PL340906A1 (en) Adamantane derivatives
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
ES2063202T3 (es) Nuevas 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y -tionas y su uso en la prevencion o tratamiento del sida.
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
AU3808795A (en) Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal product and their intended use in anticancer treatments
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
AU3478600A (en) Treatment of autoimmune diseases with american ginseng extract
AU4749900A (en) Inactivated microorganisms comprising soluble and/or solubilizable substances having pharmacological activity and/or nutritional substances having pharmacological activity, the process for their preparation and their uses thereof
AU5870298A (en) 1,4-dihydropyridin derivatives and their use in therapy
CO4790095A1 (es) Derivados de tienoxacinona inhibodores de la proteasa del herpes
AR006437A1 (es) Uso de monohidrocloruro de n-(endo-9-metil-9-azabiciclo [3.3.1]non-3-il)-1- metilimidazol-3-carboxamida, para la fabricacion de un medicamento para eltratamiento o la profilaxis de diarrea y una composicion farmaceutica que lo contiene
CA2162468A1 (en) Use of nona- and decapeptides in the preparation of a drug for the treatment of aids
PL322847A1 (en) Condensed b-carbolins
TW333453B (en) Pharmaceutical composition comprising toremifene for use in the treatment of autoimmune diseases
GEP20043348B (en) Pyrazolopyrimidinone Antianginal Agents

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 703786

Country of ref document: ES